Note: Italic page numbers refer to tables.

Abalaka, Jeremiah, 102 Affordable Medicines Facility for Malaria, 33 Africa: infectious disease burden of, 6, 18; malaria as endemic to, 27, 38, 122, 167n13, 181n57; and smallpox, 107; stereotype as infectious continent, 78, 95, 106; and stereotypes of HIV infection, 93-94, 95. See also specific countries African Institutions Initiative, 161 African medical systems: and clinical recordkeeping, 65, 125-26, 181n4; colonial model of health care system as template for, 131, 132-33, 135; development of, 142; and health care access, 18, 24, 28, 45, 155; impersonal nature of, 65–66, 143–44; inadequacy of, 5, 6, 20, 35; medical pluralism in, 25, 135; and medical research, 158, 185n56; in modern environment, 4, 19; role of, 163n2; successful programs of, 106; Western models for, 18, 149-50. See also diagnostic development; diagnostic insufficiency; indigenous medicine; laboratory diagnostics African Network for Drugs and Diagnostic Innovation, 161 AIDS (acquired immune deficiency syndrome): AIDs-related syndromes, 179n34; clinical case definition for, 105; and diagnostic insufficiency, 96, 102, 178n24; etiologic agents of, 93, 96, 97; and intestinal parasite infection rates, 138; myths surrounding, 178n14; and Nigeria, 67-68, 94, 100-102; prevalence of, 98, 100-101; skepticism about, 94, 95-96, 98, 177n4; stigma associated with, 97, 99; treatment for, 101-2, 178n24, 178n25; vaccines for, 102, 103-4; and vulnerability to diseases resembling typhoid, 49; and Western medicine, 103 American Society for Clinical Pathology, 154 American Society for Microbiology, 149, 154 American Society of Tropical Medicine and Hygiene, 122-23 Angola, 34, 69, 72, 170n58, 184n13 Anikulapo-Kuti, Fela, 98-99

anthrax, 16, 127, 184n13 antimicrobials: appropriate application of, 7, 127; and drug resistance, 44, 50-51, 54, 57, 62, 63, 115, 150, 155; lack of profitability in development of, 53, 63; narrow-spectrum, 57; overprescribing of, 53, 115, 131; selective pressure from drug use, 51, 62, 114, 124, 126, 183n9; and susceptibility testing, 58, 59, 60, 156; types of, 171n4 antiretroviral drugs, 97, 98, 101, 102, 103-5 Aro confederation, 21–22, 166n2 Aro-Ndizuogu, Nigeria, 21-24 artemether-lumefantrine, 33, 169n37 artemisinin, 171 n4 artemisinin-based combination therapies (ACTs), 33, 34, 62, 123, 159, 168n32 Asia: and malaria, 27, 36, 50; and smallpox, 107; and typhoid fever, 46, 48, 170n3 Attah, Sefi, 11

BACTEC instrumentation, 121 bacteremia, 41, 42 bacterial infections: and child mortality, 41, 54, 55, 56; clinical diagnosis of, 127; diagnostic tests for, 46-48, 57, 145, 148, 155, 156, 161; and fevers, 37; identifying, 44; malaria confused with, 29, 40, 41, 43, 47; and susceptibility testing, 59; treatment of, 56–57; vaccines for, 115 bacteriology, 15, 16, 56, 164n12, 164-65n13, Bank-Anthony, Mobolaji, 66, 173n3 Banu, Rahima, 109 Barker, Robert H., 136 Bassi, Agostino, 14 Bill and Melinda Gates Foundation, 123-24 Biosafety Level 4, 76, 156 Bosompem, Kwabena, 140 Botswana, 94, 100, 119, 120, 149, 177n4 Böttger, Eric, 46 Brazil, 88 Brefeld, Julius Oscar, 15 Brock, Thomas, 7, 166n19

Brown, Richard C., 56 Brundtland, Gro Harlem, 33

Cameroon, 46, 111, 175n38, 181n10 Campbell, Carlos "Kent," 176n71 cancer: diagnostic tests for, 47; liver cancer, 91, 92, 105 Cather, Daniel W., 135 causation: and confounding infections, 38, 126; Koch's work on, 16, 165n15, 165n18; and microbes, 14, 15-16; and precision in diagnosis, 17; prescribing medications without ascertaining, 20, 32, 33, 36, 43, 53, 56-58, 60, 127, 132, 135; Salmon's work on, 165n18. See also etiologic agents Chan, Margaret, 123 Chigwedere, Pride, 97 children: cognitive damage from fevers, 26, 167n10; and diagnostic tests for malaria, 169n43; and diarrhea, 24, 50, 137-38, 151; and drug resistance, 50; fever mortality rate, 26, 41; infection mortality rate, 54, 55, 56; and influenza antibodies, 170n6; malaria infection rate, 37; malaria mortality rate, 27, 40, 50, 55, 124; measles mortality rate, 112, 113; mortality rate of, 24, 26, 29, 41, 167n21; neonatal infections, 54-57, 131; respiratory infection mortality rate, 115; and sexually transmitted diseases, 92-93; vulnerability to diseases resembling typhoid, 49 chlamydial infections, 92-93, 140, 146 chloramphenicol, 12, 44, 126–27, 164n5 chloroquine: as antimalarial, 9, 10, 168n32; distribution of, 52; resistance to, 50, 62, 122, 124; as synthetic, 171n4 cholera, 16, 52, 69, 151 clinical record-keeping, 13, 65, 125-26, 127, 181 n4 Clinton Foundation, 154 Cohen, Gary M., 157 colonial model of health care system: and AIDS, 95; and clinical record-keeping, 181n4; diagnostic insufficiency rooted in, 7-8, 127, 131, 136, 150; and drug resistance, 52-53; and imposition of Western medicine, 127-28, 163n2; and infectious diseases, 129, 130, 182n16; and laboratory diagnostics,

129, 132, 182n15; and medications, 129,

and sexually transmitted diseases, 94-95;

as template for African medical systems,

183n6

Congo, 72, 89, 180n28

130-31, 132, 182n18; objectives of, 128-29;

131, 132-33, 135; and unitization, 110, 143,

Conteh, Aniru S., 86, 87
Cook, Albert, 178n9
Cote D'Ivoire, 149
Cunningham, Andrew, 14
curative medicine, 5, 19, 133, 135, 151, 155
cures: and accuracy of blood culture results,
42; AIDS cure claims, 101, 102; benefits of
curing infections, 63; confirming diagnosis, 56; and indigenous medicine, 127; and
Western medicine, 57

DALY (disability-adjusted life year), 118
Davies, J. N., 178n9
deBary, Anton, 164n10
Declaration of Alma-Ata, 156
developing countries: diagnostic insufficiency
in, 6; education in, 148; hospital conditions
in, 142–43; and infectious diseases, 138; and
laboratory diagnostics, 41, 151, 156; and
medications, 182–83n43; and molecular
tests, 136; and trial-and-error treatment, 56;
and tuberculosis, 118
diagnosis: abuse balanced with sufficiency,

diagnosis: abuse balanced with sufficiency, 163n4; and antimicrobial conservation, 54; clinical diagnosis of malaria, 26, 28, 29, 34, 40, 41, 46, 62, 160, 167n16; and clinical record-keeping, 125–26, 127; differential diagnosis, 7, 153, 155, 160; and disease control, 7, 109–11, 119, 122; and health practitioners, 6, 18, 29, 75, 127, 143; of hepatitis, 91–92; and indigenous medicine, 17, 19, 57–58, 127, 134; of measles, 113; and outpatient clinics, 2–3; parasite-based diagnosis of malaria, 27, 35, 36, 40, 62, 159, 169n43; precision in, 5, 6, 7, 15, 16, 17, 19, 41, 109, 115, 122, 124, 127, 143, 150, 155, 163n3, 181n4; presumptive diagnosis, 56, 125–26

diagnostic development: advocacy of, 13, 35–36, 56, 61, 154–61; and African scientists, 146–47, 155, 160–61, 184n23, 186n64; and AIDS, 105; challenges of, 46, 170n13; and disease control, 36, 112, 115, 121, 155, 180n23; feasibility of, 8, 142–52; and individualization, 110, 143–44; models for, 138–40, 154–61; optimizing health care delivery with, 136; sustained commitment to, 152–54

diagnostic insufficiency: acceptance of, 133–35; and AIDS, 96, 102, 178 n 24; and drug quality assurance, 63; and Ebola outbreaks, 7, 74, 75, 77–80, 82, 174 n 17; and HIV, 7, 98, 100, 102–3; and infectious diseases, 3–4, 97, 138–40; and Lassa fever, 87–88; levels of, 58; and medical protocols,

3–5, 20, 29, 160; and polio eradication, 112; and preventive measures, 152; and primary care centers, 26, 134–35; rooted in colonial model of health care system, 7–8, 127, 131, 136, 150; solutions to, 138–40; and technical expertise, 147; transmission exacerbated by, 5–6; and tuberculosis, 119; in Western-style clinics, 19

diagnostic reagents: costs of, 60, 144, 153, 157, 183n10, 183n11; local production of, 60, 129–30, 144, 157; and malaria diagnostic tests, 30, 31; and molecular tests, 168n29; and preliminary identification, 16; quality of, 64; storage of, 44, 139, 157, 183n10; as testing component, 55, 139, 152

diagnostic tests: for bacterial infections, 46-48, 57, 145, 148, 155, 156, 161; costs of, 6-7, 31-34, 45, 46, 60, 140, 144-45, 160; doctor's order required for, 12; for Ebola, 75-78, 80; for endemic diseases, 6, 168n29; for epidemic diseases, 6, 75, 77-79; for hemorrhagic viral infections, 76-78, 81-83, 88-89; for hepatitis, 138, 139, 147; for HIV, 47, 55, 76, 96–98, 102, 104–5, 137-39, 145, 147, 154, 156, 159, 178n12; for Lassa fever, 85, 86, 87-88, 90; local development and manufacture of, 155; for malaria, 30-37, 46-47, 55, 120-21, 136-38, 140-45, 148, 155-57, 159, 167nn22-24, 168n25, 168n28, 169n41, 169nn43-44, 183n9; molecular tests, 62, 76, 121, 136-37, 139, 146, 168n29; multiplex tests, 47, 145, 155; point-of-care tests, 47, 93, 105, 121, 139, 140, 145, 146, 147, 148, 150, 156, 157, 170n13, 184n13; quality assurance for, 1, 32, 44, 60, 61, 63, 89, 158, 159; for sexually transmitted diseases, 93, 95, 96, 144, 148, 155, 158, 177n3; time needed for, 142-44; for tuberculosis, 55, 137, 145-48, 150, 156; for typhoid, 12, 43-47, 49, 145, 170n13; usefulness of early testing, 170n7; for viral infections, 47, 155

diarrhea: and children, 24, 50, 137–38, 151; diagnostic tests for, 57–58, 145–46, 150; and Lassa fever, 80; and mortality rate, 128; multiplex tests for, 155; *Salmonella* causing, 43, 49

disease control: cost effectiveness of, 109–10; and diagnostic certainty, 7, 109, 122; and diagnostic development, 36, 112, 115, 121, 155, 180n23; and eradication challenges, 111–14; and eradication successes, 107–11; and geographic area, 115; and guinea worm, 106, 110–12, 115, 179–80n17; and Hib,

115-16, 180n35; and individualization, 110; ineradicable diseases, 115-21; and infectious diseases, 6, 7, 35, 51, 53, 63, 68-69, 72-73, 81, 88, 104-5, 115, 132, 151, 155, 174n22, 174n24, 176n54; and laboratory diagnostics, 106, 112-14, 118-21, 155, 180nn22-23, 180-81 n43; and malaria, 35, 36-37, 122-24, 138, 160, 181n57; and measles, 106, 112-14, 115, 180n26, 180n28; and pneumococcus, 115, 116; and polio, 106, 111-12, 115, 180n22; and role of diagnosis, 7, 109-11, 119, 122; and smallpox, 106, 107-12, 114-15, 124; and tuberculosis, 117-21, 180-81n43; and yaws, 111, 114, 132, 183n6 Disraeli, Benjamin, 94, 177n5 Domagk, Gerhard, 52 DOTS (directly observed short course therapy), 117-20 Dougan, Gordon "Doog," 46 Doyle, Arthur Conan, 143 drinking water. See water supply drug resistance: and antimalarial drugs, 50, 61-62, 124; and antimicrobials, 44, 50-51, 54, 57, 62, 63, 115, 150, 155; containment of, 171n13; history of, 52-53; and HIV, 105; identification of, 137; and misuse of medications, 7, 30, 33, 35, 57, 62, 126-27, 132; role of misdiagnosis in, 6, 32; and susceptibility testing, 53–54, 56, 59–64, 172n27; and tuberculosis, 117, 119, 120, 121; and typhoid fever, 126; and vaccines, 116, 117 drugs. See medications

Ebola virus: bat species as reservoirs of, 71, 84, 89; hospital-acquired infections versus community-acquired, 72, 84; localization of, 89; as notifiable disease, 176n54; origins of, 71, 174n15; outbreaks of, 70, 71-75, 84, 174n17, 174n19; and primates, 71, 174n16; retrospective confirmation of, 175n28; role of diagnostic insufficiency in, 7, 74, 75, 77-80, 82, 174n17; treatment of, 73-74, 78 Ehrlich, Paul, 51-52, 171n7 Elujoba, Anthony, 101, 102 emergent diseases, 70, 80, 83, 144-45, 152-54 endemic diseases: and confounding infections, 46; and diagnostic precision, 19; diagnostic tests for, 6, 168n29; surveillance systems for, 80, 89. See also malaria Eniola, Adewunmi, 99 enteric fevers, 43, 48, 49, 74, 158. See also typhoid fever epidemic diseases, 6, 75, 77-82, 119 Essex, Myron, 97

Ethiopia, 56, 60, 119, 159, 168n25 etiologic agents: of AIDS, 93, 96, 97; defining of, 6, 14, 53, 58, 81, 127, 132; of febrile disease, 34; Koch's work on, 16; of Marburg virus, 72; Salmon's work on, 165n18 Evans, Jennifer A., 41

faith healing, 19, 24-25, 135, 166n6 falciparum malaria: clinical diagnosis of, 40, 41; cyclic blood stage, 28, 38-40; diagnostic tests for, 30, 167n22, 167n23; and drug resistance, 50; signs and symptoms of, 25, 30, 40; and transfusion risks, 40, 103; treatment of, 27, 40; typhoid confused with, 46 Farmer, Paul, 29, 166n5 Feierman, Steven, 127 fevers: causes of, 37, 38; and colonial model of health care system, 131; diagnosed as malaria, 7, 9, 18, 25-27, 29, 30, 32, 166n7; diagnostic protocol for, 47, 150; differential diagnosis of, 155, 160; enteric fevers, 43, 48, 49, 74, 158; and infectious diseases, 25, 37, 80; laypeople's recognition of, 25, 28, 166n7; treatment of, 21, 32, 38, 155, 166n7. See also typhoid fever Fleming, Alexander, 52, 172n27 flesh-eating bacteria, 52, 171n10 Foundation for Innovative New Diagnostics (FIND), 159

Gabon, 89, 170n6 The Gambia, 48, 54-55, 102, 115-16, 119, Garrett, Laurie, 126, 177n76 Garrett, S. D., 172n30 Gaskell, Elizabeth, 165n17 Gerhadt, Carl, 3 Ghana: and AIDS, 94, 102; and child mortality from fevers, 41; and guinea worm, 111; laboratory diagnostics in, 129, 134, 140-42, 147, 172n34, 185n56; and tuberculosis, 119; and vaccine for yellow fever, 70; Western medicine in, 19, 133, 134; and yaws, 114 global economic crisis, 144, 154 Global Health Program, 123 Goethe, Johann Wolfgang von, 161 gonorrhea, 92-93 Groopman, Jerome, 18, 79 Guinea, 84, 87, 90 guinea worm, 106, 110-12, 115, 179-80n17

Hantavirus, 17–18 Hardin, Garrett, 63 health, defining of, 65, 173n2 health practitioners: and AIDS, 96, 98, 102; and colonial model of health care system, 128-29; and diagnosis, 6, 18, 29, 75, 127, 143; and diagnostic tests, 31; doctors infected with Lassa fever, 82-88; and international experts, 89, 90; licensing of, 163n2; local technical expertise myths, 147-49; medications dispensed by, 12, 24, 37, 52-53, 58, 65, 130; and microscopy, 4; and patient records, 125; and patient recovery, 18-19; safety of, 68, 72, 73, 89; and staffing levels, 65, 68; training of, 6, 68, 131, 133, 135, 147-49, 154, 174n22; and tuberculosis, 119, 121; unsanctioned practitioners, 19, 25, 69, 119, 156, 161, 163n2; vaccines for, 92; village health workers, 34, 37; work load of, 142-43 hemorrhagic viral infections: diagnostic tests for, 76-78, 81-83, 88-89; and fevers, 37; hospital outbreaks of, 68-69, 71-76, 81, 84, 88, 90; malaria confused with, 73-74, 78-80, 82, 84-85; mortality rate, 69-71, 78, 80, 81; and quarantine, 58, 72, 74, 78, 81, 82; transmission of, 71, 72–73, 78, 89, 90; treatment of, 73-74, 78, 81. See also Ebola virus; Lassa fever; Marburg virus; yellow fever Henle, Friedrich Gustav Jacob, 14, 38, 165n15 hepatitis, 40, 91-92, 138-39, 147 hepatitis B virus, 91, 92, 103, 105, 138, 139, 147 herbal remedies, 17, 101, 102, 127, 128 Hesse, Fannie, 16 Hesse, Walter, 16 Hib (Haemophilus influenzae type B), 41, 115–16 Hippocrates, 13 Hippocratic Oath, 14 HIV (human immunodeficiency virus): denialist hypotheses, 96-100; and diagnostic insufficiency, 7, 98, 100, 102-3; diagnostic tests for, 47, 55, 76, 96-98, 102, 104-5, 137-39, 145, 147, 154, 156, 159, 178n12; HIV-associated dementia, 179n34; and laboratory diagnostics, 97, 102, 103-5, 157, 158; and measles vaccination, 113; and needle reuse, 174n22; prevalence of, 94, 96-97, 98, 100, 120; risk factors for, 96, 98; skepticism about, 95, 97, 98; and smallpox eradication, 109; and stereotypes of Africa, 93-94, 95; and transfusion risks, 40, 102-3; transmission of, 98, 105; treatment of, 103-4; and tuberculosis, 117, 120, 121 Hoffman, Stephen, 123 home nursing care, 11-12, 28

Hudson, Rock, 98

Ibadin, Michael O., 45 Idris, Ali, 72, 174n23 Ikeja General Hospital, Lagos, Nigeria, 63-64, 66-68, 125-26, 173n5 India, 64, 108, 112, 118, 131 indigenous medicine: Africans' reliance on, 24, 128, 134, 135; and AIDS, 101-2, 178n25; costs of, 69; and diagnosis, 17, 19, 57-58, 127, 134; and Ebola virus, 78; education of doctors, 182n19; indigenous practitioners as sanctioned, 163n2; investments in, 5; and medical pluralism, 25; and missionary health care, 130; and sorcery accusations, 24, 26, 166n5; surgical burial sites, 81, 82, 174n25; as term, 163n2; and tuberculosis, 119; and vaccines, 108

infectious diseases: cause and nature of, 4, 13-14, 150; and colonial model of health care system, 129, 130, 182n16; confounding infections, 32, 37-38, 46-47, 126, 157-58, 176n71; and diagnostic insufficiency, 3-4, 97, 138-40; and disease control, 6, 7, 35, 51, 53, 63, 68–69, 72–73, 81, 88, 104–5, 115, 132, 151, 155, 174n22, 174n24, 176n54; and drug resistance, 50; and fevers, 25, 37, 80; and microbiology, 4, 14, 128; neonatal infections, 54-57; nonspecific clinical signs for, 18, 29; rapid diagnostic tests for, 31, 168n28; as self-resolving, 19; treatment for, 26, 32 influenza: avian influenza strains, 80; Hib, 41, 115-16; malaria confused with, 42, 170n6; pandemic potential of, 80, 176n54; polio confused with, 112

Program, 149 International Monetary Fund, 59 intestinal perforation, 12, 43, 47 invaliding, 128 Iraq, 152–53, 184–85n42, 185n43 Irrua Specialist Teaching Hospital, 85, 176n72

International Laboratory Capacity Building

Janssen, Zacharias, 164n8 Janzen, John, 127 Jenner, Edward, 108, 179n9 Jetsy, Benjamin, 179n9 Jones, Edward, 119

Kenema Government Hospital, 85, 87, 177n76 Kenya: and clinical record-keeping, 126; and Ebola virus, 90; laboratory diagnostics in, 41–42, 149, 158; and malaria, 33, 37, 169n37; and Marburg virus, 72; and nontyphoidal *Salmonella*, 49, 171n20; and Rift Valley fever, 184n13 Kenya Medical Research Institute (KEMRI), 147 Kim, Jim Yong, 103, 137–38 Klebs, Edwin, 164–65n13 Klugman, Keith, 145 Koch, Robert, 14, 15–16, 127, 164n8, 164n10, 165n15, 165n18, 166n19 Kochi, Arata, 35 Koprowski, Hilary, 111 Korle-Bu Teaching Hospital, Accra, Ghana, 46, 63, 185n56 Kumasi, Ghana, 41, 48, 60

laboratory diagnostics: access to, 45, 155; and blood cultures, 41-46, 160, 186n62; and colonial model of health care system, 129, 132, 182n15; cost effectiveness of, 46, 144-45, 183n9; costs of, 60-61, 144-45; decentralizing facilities, 155-56; development of, 8, 42, 104, 105; and disease control, 106, 112-14, 118-21, 155, 180nn22-23, 180-81n43; and donor priorities, 137; and dysentery, 57-58; emerging technologies, 7, 136-37, 138; and fevers, 37, 38; field laboratories, 78, 82, 89, 153; in The Gambia, 55; in Ghana, 129, 134, 140-42, 147, 172n34, 185n56; for hemorrhagic virus infections, 89, 90; for hepatitis B, 92; for HIV, 97, 102, 103-5, 157, 158; ideal tests for Africa myths, 145–47; identification of pathogens with, 5, 16-17; and infection control, 104-5; for Lassa fever, 86, 87, 88; local technical expertise myths, 147-49; for malaria, 30-34, 35, 40, 122, 124, 138, 158, 167n22; in Malawi, 160, 185n47; and medical protocols, 20; and molecular tests, 136-37; myths concerning, 142-52; in Nigeria, 61, 91, 148-49, 151, 158; and preventive measures, 151-52, 155; and regional laboratories, 156-57; and safety, 159, 186n60; superfluous diagnostic tests myth, 149-51; supply chain for, 158-59; and susceptibility testing, 58, 59-61; in Tanzania, 56, 141, 146, 149, 155; and tertiary care, 9, 133-34, 138, 142, 144, 148, 156, 185n56; time constraint myths, 142-44; and training, 131-32, 154; and tuberculosis, 118, 150, 157-58; for typhoid carriers, 48; for typhoid fever, 43-46; and Western medicine, 42, 134, 135, 150-51, 153; in Zambia, 61, 138, 149, 159

Laënnec, René, 3, 13 Lagos University Teaching Hospital, 63, 99, 173n4 Larsen, Christoph H., 157 Lassa fever, 74, 81, 82–88, 89, 173n9, 176n64, 176n71, 176n72, 177n76

Lee, Helen, 138–40, 146

Leeuwenhoek, Anton, 14, 164n8

Lesotho, 121, 145, 148, 152

Liberia, 84, 87, 90

Lister, Joseph, 165n13

Lopez, Alan D., 118

Lubell, Yoel, 32

Lujo virus, 176n62

Lyme disease, 42, 170n6

Maalin, Ali Maow, 109 Madagascar, 159 Makerere University, 103, 131 malaria: and anemia, 27, 39, 40, 74, 170n3; bacterial infections confused with, 29, 40, 41, 43, 47; and blood transfusions, 40, 96, 139; cerebral malaria, 6, 167n10, 170n3; cognitive damage from, 26, 167n10; and convulsions, 24, 25, 26, 39, 40; diagnosis by clinical signs and symptoms, 26, 28, 29, 34, 40, 41, 46, 62, 160, 167n16; diagnostic protocol for, 18, 33, 62; diagnostic tests for, 30-37, 46-47, 55, 120-21, 136-38, 140-45, 148, 155-57, 159, 167nn22-24, 168n25, 168n28, 169n41, 169nn43-44, 183n9; and disease control, 35, 36-37, 122-24, 138, 160, 181n57; as endemic to Africa, 27, 34, 36, 38, 167n13, 181n57; eradication efforts, 33, 35-36, 107, 111, 122, 123-24, 168-69n37, 169n47, 181n57; fever diagnosed as, 7, 9, 18, 25-27, 29, 30, 32, 166n7; hemorrhagic viral infections confused with, 73-74, 78-80, 82, 84–85; history of, 14, 27; influenza confused with, 42, 170n6; and invaliding, 128; and laboratory diagnostics, 30-34, 35, 40, 122, 124, 138, 158, 167n22; Lassa fever confused with, 176n71; mortality rate of, 24, 38, 170n3; nonspecific signs and symptoms of, 28, 128; parasite-based diagnosis of, 27, 35, 36, 40, 62, 159, 169n43; prevalence of, 12, 29, 36, 50, 164n4; and self-medication, 167n16; and temperature charts, 45-46; treatment of, 25, 27, 28, 32, 33-34, 35, 40, 128, 169n41, 170n3; typhoid confused with, 42-43, 45-46, 48, 49. See also falciparum malaria

malaria
malaria parasites (*Plasmodia*), 27–29, 31,
38–41, 61, 122, 167n22, 168n29, 170n3
Malawi, 41, 49, 148, 160, 171n20, 185n47
Mali, 94, 111, 116
Mallon, "Typhoid Mary," 48
Mano River Union Lassa Fever Network, 87, 90

Maputo Declaration on the Strengthening of Laboratory Systems, 154, 158, 185n55
Marburg virus, 69, 70–73, 80, 89, 174n19, 176n54, 184n13
Maude Commission, 129
Mbeki, Thabo, 94
McNerney, Ruth, 119
measles, 106, 112–15, 167n16, 180n26, 180n28
Medécins Sans Frontières (MSF, Doctors without Borders), 69, 140
Medical Research Council–Gambia, 54–55, 115–16
medications; and calonial model of health care

medications: and colonial model of health care system, 129, 130-31, 135, 182n18; and combination therapy, 117; costs of antimalarial drugs, 32-34, 62, 168n32, 169n41; and developing countries, 182-83 n43; diagnostics partnered with, 33-34, 62, 63, 144, 150, 151, 153, 155, 159-60, 169n41; and dispensaries, 130-33, 155, 182n18; drug development, 6, 35; for fevers, 25; health practitioners' dispensing of, 12, 24, 37, 52-53, 58, 65; hospitals' dispensing of, 67–68; introduction of Western pharmaceuticals, 19; judicious use of, 6, 7; manufacturer donation program, 168n36; motivations for obtaining, 65; and needs of developed world, 145; pharmacists' dispensing of, 12, 24, 37; prescribing of antimalarial drugs, 47, 53; prescribing without ascertaining causation, 20, 32, 33, 36, 43, 53, 56-58, 60, 127, 132, 135; quality of, 63, 64, 78; and specific indications, 126. See also drug resistance

Meless, Hailu, 60

men: and measles, 113; protective effect of male circumcision, 100; and sexually transmitted diseases, 93

meningitis, 51, 52, 79, 88, 115, 140 microbes, 13–17, 50–51, 53, 165n18 microbiology, 4, 7, 14–16, 41, 127–28, 164n12, 165n15

microscopy: and diagnostic tests for malaria, 30–31, 33–34, 40, 141–42, 167n22, 169n44; electron microscopy, 39, 165n18; and general hospitals, 156; and infectious diseases, 15; invention of microscopes, 4, 14, 164n8; skills for, 30, 31, 168n25; and tuberculosis, 118–21, 142, 148, 180–81n43; underutilization of, 147

Millennium Development Goal, 35, 167n21, 168n35

minimum inhibitory concentration (MIC), 59, 61, 172n27, 172n30 missionary health care, 130

molecular tests, 62, 76, 121, 136–37, 139, 146, 168n29
mosquitoes, 10–11, 69–70, 106, 122–24, 174n11, 181n57
mosquito netting, 10, 11, 35, 123, 168n37, 174n11
Mozambique, 103, 149
Muhimbili National Hospital, Dar es Salaam, Tanzania, 41, 56
Multilateral Initiative on Malaria, 35
Murray, Christopher J., 118

Namibia, 103, 149, 177n4 National Youth Service Corps, Nigeria, 66 needle reuse, 72, 84, 100, 174n22 Nigeria: "Adeola scandal," 173n1; and AIDS, 67-68, 94, 100-102; divining practices of, 57; and guinea worm, 111; and hepatitis B, 92; and HIV, 96-100; laboratory diagnostics in, 61, 91, 148-49, 151, 158; and Lassa fever, 82-87, 90, 176n69, 176n72; malaria in, 9, 43; and measles, 180n28; medical schools of, 131-32, 148; and missionary health care, 130; outpatient clinics in, 1-3; and polio, 112; and road-building projects, 22-24; and transfusion risks, 103; and typhoid fever, 127; Western medicine in, 21-22; Widal test used in, 45 Nkrumah, Kwame, 136, 182n33

Noguchi Medical Research Institute, 185n56

Nwapa, Flora, Efuru, 21, 23, 24, 25, 26, 173n6

Nuland, Sherwin, 17

nutrition, 4, 11, 49, 106, 182n16

Obafemi Awolowo Teaching Hospitals, 91 Obel, Arthur, 102 Ogbimi, A., 45 Ojo, 'Segun, 91, 92, 148 Onwenu, Charles, 22 Onwenu, Onyeka, 22, 166n3 Osler, William, 45 Outbreak (film), 71, 76 outpatient clinics, 1–3, 19, 149–50

pandemics, 80, 176n54
Paramasivan, C. N. "Param," 157
Pasteur, Louis, 14, 15
pathogens, 5–7, 14–17, 41, 57, 68, 80, 156, 161
penicillin, 52, 92, 114, 171n4
Petri, Richard J., 166n20
Petri dishes, 16, 43, 166n20
PfEMP1, 39–40
pharmaceutical industry, 6, 17, 53, 62–63, 103
pharmaceuticals. See medications

plague, 14, 48, 140 plant biology, 164n10 Plasmodia (malaria parasites), 27-29, 31, 38-41, 61, 122, 167n22, 168n29, 170n3 Plasmodium falciparum, 28, 30, 31, 35, 39-40, 167n15, 181n57. See also falciparum malaria Plasmodium ovale, 31, 167 n15 Plasmodium vivax, 31, 167n15 Plett, Peter, 179n9 pneumococcus, 41, 42, 115, 116 pneumonia, 4, 115 Polage, Christopher R., 159 polio, 106, 111-12, 115, 180n22 polymerase chain reaction (PCR), 31, 62, 121, 175n31, 181n43 preventive measures: implementation of, 4-5, 11, 145; and laboratory diagnostics, 151-52, 155; for malaria, 50; neglect of, 133; and

primary care centers: and diagnostic insufficiency, 26, 134–35; diagnostic tools of, 25, 40, 134, 145, 148; and dispensaries, 132–33; and laboratory diagnostics, 155–56; and malaria treatment, 169n41; and susceptibility testing, 60

vaccines, 106, 135, 179n3

primates, 71, 89, 100, 174n16, 175n38 public health: and blind drug prescribing, 60; and colonial model of health care systems, 128–29; and costs of eradication, 115; and diagnostic development, 151, 161; and education, 81–82, 90; and epidemics, 79; and individualization of health care delivery, 110; and malaria, 36; role of diagnosis in, 110; role of scientific knowledge in, 4; successful programs of, 106; and threat of infection, 51; and tuberculosis, 117–19. See also disease control

Pyrimethamine, 164n2

quinine, 128, 171n4

Ransome-Kuti, Beko, 99
Ransome-Kuti, 'Funmi, 99
Ransome-Kuti, Olikoye, 99
Rapataski, Brandy, 105
ratchet effect, 6
Reddish, George F., 172n27
reverse transcriptase-PCR (RT-PCR) test, 76, 83, 175n31
ribavirin, 85
Rift Valley fever, 173n9
river blindness, 106, 179n2
Roll Back Malaria program, 33, 35–36, 168–69n37, 169n47

Roosevelt, Franklin D., 111 Ross, Ronald, 27, 167n12 Royal Victoria Teaching Hospital, Banjul, The Gambia, 55 Rwanda, 103, 149

Sabin, Albert, 111 Salk, Jonas, 111 Salmon, Daniel, 165n18 Salmonella, 41, 43, 44, 45, 47, 48, 49 sanitation, 11, 47, 129 Schatz, Albert, 117 Schram, Ralph, 130, 173n6 Schroeter, Joseph, 15, 16 secondary care centers, 40, 60, 66, 134, 148, 156 Selwyn-Clark, P. C., 19 Semmelweiss, Ignaz, 18 Senegal, 97 sepsis, treatment of, 56, 172n18 septicemia, 42 severe acute respiratory syndrome (SARS), 79, 175n43 Sexually Transmitted Bacteria lab, 61 sexually transmitted diseases: diagnostic tests for, 93, 95, 96, 144, 148, 155, 158, 177n3; role of diagnostic insufficiency in, 7, 92-93. See also AIDS (acquired immune deficiency syndrome); HIV (human immunodeficiency virus); syphilis Shillcutt, S., 183n9 Sierra Leone, 83, 84, 85, 87, 88, 90 Slater, Alexander Ransford, 19 smallpox, 106-12, 114-15, 124, 179n5, 179n9 Snow, John, 18, 69 Snow, Robert, 36 South Africa: and AIDS, 94, 102, 177n4; and Ebola virus, 78; and laboratory diagnostics, 149; and Lassa fever, 83, 86; and transfusion risks, 103; and tuberculosis, 119, 120, 121 South America, 36, 70, 107 South Asia, 48 spiritualist churches, 24-25, 166n6 spiritual remedies, 17, 101, 102, 127 Streptococcus pneumoniae, 41, 42, 115, 116 Sudan, 72, 78, 90, 94, 111, 174n19, 174n24 Sulayman Jungkung General Hospital, The Gambia, 55, 56 sulfadoxine-pyrimethamine (Fansidar), 50, 62, 168n32, 171n4 sulfa drugs, 52

Sunday-Sunday medicine, 10, 164n2

surveillance systems: for endemic diseases,

80, 89; for Hib, 115-16, 180n35; for HIV,

Suppe, Frederick, 105

116–17; for polio, 112; sentinel surveillance sites, 54, 61, 97, 121 susceptibility testing: availability of, 55, 120–21, 158; costs of, 60–61, 173n41; diffusion tests, 59, 172n27, 172n30; dilution tests, 59, 61, 172n27, 172n30; E-test, 61, 172n30; feasibility of, 59–64; location-specific data on, 56, 58; for preventing drug resistance, 53–54, 56, 59–64, 172n27 Swaziland, 57 syphilis, 51, 92–94, 96, 105, 114, 178n9

97, 98; for measles, 114; for pneumococcus,

Tagbaru, Belete, 60

Tanzania: and AIDS, 105; decline in febrile infections, 36–37; divining practices of, 57; and laboratory diagnostics, 56, 141, 146, 149, 155; and malaria, 41; Mto wa Mbu, 36; and nontyphoidal *Salmonella*, 171 n20

tertiary care teaching hospitals: equipment of, 55; and laboratory diagnostics, 9, 133–34, 138, 142, 144, 148, 156, 185n56; and susceptibility testing, 60

Theiler, Max, 174n10
Thomas, Lewis, 19
Thwing, Julie, 34, 170n58
tissue culture, 165n18
Togo, 170n6
tragedy of the commons paradigm, 63

transfusions, 40, 96, 102-3, 139

treatment: for AIDS, 101–2, 178n24, 178n25; of bacterial infections, 56–57; basis of, 18; and diagnostic insufficiency, 3–5; and diagnostic precision, 5, 16, 127, 155–56; as diagnostic tool, 56; of fevers, 32, 38, 155; of hemorrhagic viral infections, 73–74, 78, 81; of HIV, 103–4; inadequacy of, 56, 66; for infectious diseases, 26, 32; of malaria, 25, 27, 28, 32, 33–34, 35, 40, 128, 169n41, 170n3; of sepsis, 56, 172n18; and Western medicine, 5, 13, 26 Troup, Jeanette, 83

Tshabalala-Msimang, Manto, 94 tuberculosis: and AIDS, 105; and artists, 117, 180n39; cause of, 14, 16, 165n17; and colonial model of health care system, 182n16; and diagnostic delay, 151, 166n8; diagnostic tests for, 55, 137, 145–48, 150, 156; and disease control, 117–21, 180–81n43; exceedingly drug-resistant tuberculosis, 119–21; Koch's work on, 16, 127, 165n15; and laboratory diagnostics, 118, 150, 157–58; and measles, 113; multidrug-resistant tuberculosis, 117, 119–21, 137–38, 152; and streptomycin, 52

Tubex, 170n13
Tulane University, 87
Turshen, Meredith, 181n4
Twain, Mark, 177n5
Twumasi, P. A., 133–34
Typhidot, 170n13
typhoid fever: carriers of, 44, 48, 49; chloramphenicol for, 12, 44, 126–27, 164n5; diagnostic tests for, 12, 43–47, 49, 145, 170n13; hemorrhagic viral infections confused with, 73–74, 78–80; malaria confused with, 42–43, 45–46, 48, 49; mortality rate for, 12, 128

Uganda: and AIDS, 100, 103-4; and diagnostic tests, 159; Gulu Ebola outbreak, 69, 77-80, 82, 176n55; and HIV, 94; Kikyo Ebola outbreak, 79-80; and Marburg virus, 174n19; and syphilis, 94-95, 178n9; and tuberculosis, 119 Ugandan Ministry of Health, 47 University College Hospital, 10, 164n1 University of Ghana Medical School, Accra, Ghana, 61, 147, 172n34 University of Ibadan, Nigeria, 84, 131, 147 University of Nigeria Teaching Hospital, 84 University Teaching Hospital, Lusaka, Zambia, 61, 136-37, 138, 148, 182n37 U.S. Army Medical Research Institute of Infectious Diseases, 87

U.S. Centers for Disease Control (CDC): and Brazilian Purpuric Fever, 88; and Ebola virus, 77–80, 82, 175n28; field laboratories of, 153; and guinea worm eradication, 111; and laboratory diagnostics, 154; and Lassa fever, 85, 87; and quality assurance for diagnostic tests, 159; and typhoid fever, 47 U.S. Clinical Laboratory Standards Institute

(CLSI), 154 U.S. President's Emergency Plan for AIDS Relief (PEPFAR), 154

vaccines: for AIDS, 102, 103–4; for bacterial infections, 55, 115; development of, 4, 35, 39, 46–49, 51–52, 55, 145–46, 151–52; for hepatitis B, 92; and herd effect, 116–17; for Hib, 115–16; and infectious disease control, 7; for malaria, 35, 39, 122; for measles, 112–14, 180n26; for pneumococcus, 116–17; for pneumonia, 4; for polio, 111; and preventive measures, 106, 135, 179n3; Salmon's work on, 165n18; for sexually transmitted diseases, 92; for smallpox, 108–9, 179n9; for yellow fever, 70, 90, 177n85

var genes, 39
variolation, 108
Vaughan, Megan, 94, 110, 138, 178n9, 183n6
vector control, 11, 106, 122, 124
viral infections: diagnostic tests for, 47, 155;
epidemic potential of, 80; malaria confused
with, 40, 42. See also hemorrhagic viral
infections
virology, 90, 112, 165n18

Waksman, Selman, 117
Wasserman tests, 95, 96
water supply: and general hospitals, 68; and guinea worm, 110, 111; safety of, 4, 10, 11, 106, 128, 151

Wellcome Trust, 138, 161
Western medicine: and AIDS, 103; and diagnostic precision, 17–19, 127; and dispensing of medications, 130; education of doctors, 182n19; evidence-based approach of, 18, 19, 54; and hemorrhagic virus infections, 73, 81; history of microbes, 13–17; and HIV, 105; and infection control, 81; and laboratory diagnostics, 42, 134, 135, 150–51, 153; and medical pluralism, 25, 135; parallels with diviner's consultation approach, 57–58; as term, 163n2; and treatment, 5, 13, 26; trust in, 21, 82

Widal, Geroges-Fernand-Isidor, 44 Widal test for typhoid, 12, 44–47, 96, 170n13 Wirth, Dyann, 136 women: and diagnostic delay, 166n8; and HIV,

96; and sexually transmitted diseases, 92–93 Wootton, David, 5 World Bank, 59, 118, 154

World Health Assembly, 107, 109, 111, 179n17
World Health Organization (WHO): and antiretroviral drugs, 103, 105; defining health, 173n2; and diagnostic tests, 146, 152, 159; and drug resistance, 53, 62, 171n13; and Ebola virus, 75, 78; and field laboratories, 153; and laboratory diagnostics, 154; and Lassa fever, 87; and malaria, 25, 28, 32–36, 123, 169n43; and Marburg virus, 72; and measles, 113–14; and notifiable diseases, 176n54; and polio, 112; and sepsis treatment, 172n18; and smallpox, 107, 109; and tuberculosis, 117; and typhoid, 126; and yaws, 132

World Malaria Report (2008), 35 wound fever, 16

Yamada, Tadataka, 123–24 Yambuku Catholic Mission Hospital, Zaire, 72

222 INDEX

yaws, 52, 95, 111, 114, 132, 178n9, 183n6 yellow fever, 69–70, 90, 111, 128, 174n10, 177n85 Yorke, James, 105 Ypres papyrus, 56

Zaire: Kikwit Ebola outbreak, 73, 74–77, 77, 78, 80–82, 175n28, 175nn35–37; and laboratory diagnostics, 56; and Marburg,

72, 174n19; Yambuku Ebola outbreak, 72, 73–74, 75, 82, 126

Zambia: and AIDS, 100; decline in febrile infections, 36–37; laboratory diagnostics in, 61, 138, 149, 159; and malaria, 124; and measles, 113; and Roll Back Malaria program, 33, 35, 168–69n37, 169n47; and tuberculosis, 119, 149, 166n8

zoonotic infections, 90